Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 3/20 | 0.80 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CPA1 | P15085 | 2/20 | 0.62 |
| ▸ | CPB1 | P15086 | 1/20 | 0.62 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.62 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12494537 | 1.00 | CPA3 (0.80) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL26679347 | 0.95 | CPA3 (0.77) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL28430963 | 0.93 | CPA3 (0.75) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL31303730 | 0.93 | CPA3 (0.75) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL11143841 | 0.93 | CPA3 (0.75) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL28600681 | 0.93 | CPA3 (0.75) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL29088272 | 0.89 | CPA3 (1.00) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL3963424 | 0.89 | CPA3 (1.00) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL11664393 | 0.89 | FOLH1 (0.79) | CPA3FOLH1CYP1A2CPA1CPB1 | |
| SCHEMBL22612309 | 0.86 | FOLH1 (0.71) | CPA3FOLH1CYP1A2CPA1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4700124-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250326731-A1 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | SCRIPPS RESEARCH INST (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4522595-A2 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | The Scripps Research Institute (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250075208-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2025-03-06 | — | — | US | disclosed |
| US-12173288-B2 | Oligonucleotide-ligand conjugates and process for their preparation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2023220559-A2 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220559-A2 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20220348914-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2022-11-03 | — | — | US | disclosed |
| EP-4039278-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-3019200-B1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | ALNYLAM PHARMACEUTICALS INC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-6262195-B1 | POLYMERIZING ETHYLENE OPTIONALLY WITH ALPHA-OLEFIN IN PRESENCE OF TITANIUM OR VANADIUM COMPOUND CATALYST; CONTACTING PRODUCT WITH COMPOUND TO DEACTIVATE CATALYST, ZIRCOCENE CATALYST AND COCATALYST TO FURTHER POLYMERIZE | MONTELL TECHNOLOGY COMPANY BV (NL) | 2001-07-17 | — | — | US | disclosed |
| US-6232484-B1 | Bridged zirconocene compounds, process for their preparation and their use as catalyst components in the polymerization of olefins | MONTELL TECHNOLOGY B.V. (NL) | 2001-05-15 | — | — | US | disclosed |
| EP-0941997-A2 | Bridged zirconocene compounds, process for their preparation, and their use as catalyst components in the polymerization of olefins | Montell Technology Company bv (NL) | 1999-09-15 | — | — | EP | disclosed |
| EP-0942011-A1 | Multi-stage process for the polymerization of olefins | Montell Technology Company bv (NL) | 1999-09-15 | — | — | EP | disclosed |
| US-5911995-A | ENZYME INHIBITORS FOR TYROSINE KINASE AND CYTOTOXIC DOSAGE OF EPIDERMAL GROWTH FACTOR | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1999-06-15 | — | — | US | disclosed |
| WO-1997029779-A2 | EGF-GENISTEIN CONJUGATES FOR THE TREATMENT OF CANCER | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1997-08-21 | — | — | WO | disclosed |
| EP-0133225-B1 | PEPTIDE DERIVATIVES AND THEIR SALTS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, PROCESS AND INTERMEDIATES FOR THEIR PRODUCTION | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1988-10-19 | — | — | EP | disclosed |
| EP-0133225-A2 | Peptide derivatives and their salts, pharmaceutical preparations containing them, process and intermediates for their production | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-02-20 | — | — | EP | disclosed |
| US-4410461-A | Production of benzylic esters | ASHLAND OIL, INC. (US) | 1983-10-18 | — | — | US | disclosed |
| US-3862225-A | D-RING SUBSTITUTED TETRACYCLINES | PFIZER | 1975-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326731-A1 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | DNPH1, NISCH, PTMA | CPA3 394/4885FOLH1 150/4885CYP1A2 3500/4885 |
| US-20220348914-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | CPA3 4028/4885FOLH1 412/4885CYP1A2 4624/4885 |
| US-12173288-B2 | Oligonucleotide-ligand conjugates and process for their preparation | IGF2R, IRS1, INSR | CPA3 4028/4885FOLH1 412/4885CYP1A2 4624/4885 |
| US-20250075208-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | CPA3 4028/4885FOLH1 412/4885CYP1A2 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.